Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2016

View Archived Issues

Peloton initiates phase I trial of PT-2977 in advanced solid tumors

Dana-Farber studies DPX-E7 for incurable HPV 16-related cancers

Minoryx Therapeutics' lead candidate granted orphan drug designation in Europe

Talazoparib plus temozolomide well tolerated in children with malignancies

Eip Pharma presents positive results for VX-745 in patients with early Alzheimer's disease

Stable disease seen with BGB-324 monotherapy in non-small cell lung cancer trial

ElsaLys Biotech acquires rights to anti-CD115 antibody from Transgene

Adamis Pharmaceuticals resubmits NDA to FDA for epinephrine prefilled syringe

E.U. consortium starts work on Zika vaccine based on measles vector

Enyo Pharma's EYP-001 safe and well tolerated in initial phase I testing

BMS's Ximency receives first approval in Japan

Gedeon Richter withdraws European applications for biosimilar pegfilgrastim

EMA's CHMP backs approval of canakinumab in periodic fever syndromes

Preclinical data support potential use of Can-Fite's CF-102 in NASH

Novartis' Votubia receives positive opinion in E.U.

EMA committee recommends approval of baricitinib for RA

Merck & Co.'s Keytruda gets positive opinion from EMA's CHMP

FDA accepts for review Ironshore's NDA for HDL-200

Aurigene describes new orally bioavailable CDK7 inhibitor AU-12122

Neridronic acid receives FDA breakthrough therapy designation in CRPS

Anti-tau monoclonal antibody ABBV-8E12 evaluated in phase I PSP study

DCB-USA and Kaohsiung Medical University describe betaG inhibitors

Antifungal agents reported in recent Pulmocide patent

Kyorin Pharmaceutical prepares and tests FPR2 agonists

Merck & Co. patents sGC activators

Ajou University patent reveals TLR2 antagonists/TLR4 modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...